SCHEMBL2263926

SCHEMBL2263926

NOCC(=O)NCC[C@H](N)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OTC P00480 1/20 0.46
GSR P00390 2/20 0.41
CYP1A2 P05177 2/20 0.41
GRM8 O00222 1/20 0.41
GRM6 O15303 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIK1 P39086 1/20 0.41
GRM5 P41594 1/20 0.41
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
SLC1A1 P43005 1/20 0.41
GRIA4 P48058 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIK2 Q13002 1/20 0.41
GRIK3 Q13003 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2263934 1.00 OTC (0.46) OTCGSRCYP1A2GRM8GRM6
SCHEMBL515567 0.88 OTC (0.54) OTCGSRCYP1A2BLMTSHR
SCHEMBL1059272 0.88 OTC (0.54) OTCGSRCYP1A2BLMTSHR
SCHEMBL2262068 0.81 GFPT1 (0.46) GGT1TSHRCTHCBSTHPO
SCHEMBL2262058 0.81 GFPT1 (0.46) GGT1TSHRCTHCBSTHPO
SCHEMBL20477200 0.79 OTC (0.50) OTCGSRCYP1A2GRM8GRM6
SCHEMBL20477199 0.79 OTC (0.50) OTCGSRCYP1A2GRM8GRM6
SCHEMBL20477197 0.79 OTC (0.50) OTCGSRCYP1A2GRM8GRM6
SCHEMBL1768369 0.79 OTC (0.50) OTCGSRCYP1A2GRM8GRM6
SCHEMBL1768374 0.79 OTC (0.50) OTCGSRCYP1A2GRM8GRM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 US disclosed
EP-2539333-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-01-02 EP disclosed
WO-2011104266-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-09-01 WO disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 OTC 4421/4885GSR 4037/4885CYP1A2 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.